Publications by authors named "Celestino Pinera-Haces"
Article Synopsis
- Hyperkalaemia is a common electrolyte imbalance in chronic kidney disease (CKD) patients, with varying prevalence among different treatment groups: 9.6% in CKD patients not on dialysis, 16.4% in those undergoing haemodialysis, and 10.6% in those on peritoneal dialysis.
- Factors associated with hyperkalaemia include decreased kidney function (measured as GFR), higher plasma creatinine levels, and the use of RAAS inhibitors, particularly in patients with diabetes or heart failure.
- New treatments that can help lower potassium levels by binding it in the gut may help CKD patients continue to benefit from RAASi without the risk of hyperkalaemia.
Background: The deficit of 25-hydroxyvitamin D (25OHD) associated with secondary hyperparathyroidism (SHPT) is a frequent finding in chronic kidney disease (CKD) patients on haemodialysis (HD). These events are associated with increased morbidity and mortality rates of cardiovascular (CV) origin. Adequate 25OHD serum levels as well as the use of selective vitamin D receptor activators (VDRA) have been shown to have beneficial and independent effects on bone mineral metabolism and cardiovascular risk.
View Article and Find Full Text PDF